ISSN: 2155-9570
Rita Szechey, Kinga Kranitz and Zsolt Nagy-Zoltan
Head of the University Department
Scientific Tracks Abstracts: J Clin Exp Ophthalmol
Objective: To study the corneal densitometric values of Fabry's disease with typical corneal vertigo, and to monitor the effect of the enzyme replacement therapy with a Scheimpflug camera Patients and Methods: The corneal densitometric values of 6 patients with Fabry's disease were compared to the eyes of 5 healthy subjects. In a hemizygotic male patient and heterozygous female patient, 2 studies were performed on both eyes with 2 years follow-up during the therapy. Measurements were performed with Scheimpflug camera Pentacam HR (Oculus Optikgerate) The results were given in standardized grayscale units (GSU). Results: The mean densitometric value for the entire cornea was significantly higher in the patient group compared to the control group. In the central layer of the corneal surface of 120 �¼m the mean densitometric values measured in the deepest 60 �¼m layer were significantly higher in Fabry patients. In the densitometric values of hemizygotic men and heterozygous women, the superficial 120 �¼m layer was found to be significantly different. In two years of enzyme replacement therapy, the density values for total cornea significantly and a significant decrease in corneal surface 120 �¼m and the lower 60 �¼m . Conclusions: 1. Fabry's disease with cornea verticillatus and subepthelial haze significantly increased densitometric values compared to normal control eyes. 2. Enzyme replacement therapy resulted in a significant decrease in Fabry's disease in corneal densitometry. In the future, the method in examining the efficacy of therapy, as well as in the standardisation of the ophthalmic parameters of the scoring system, can play a significant role.
Rita Szechey: Besides my other activities (ophthalmologic rehabilitation: vision and eyelid surgeries) I work as a consultant for Fabry -patients at the Budapest Semmelweis University. I am a member of the Fabry Patient Organization and I am committed to patient treatment and the research of the disease